Intercept Pharmaceuticals, Inc. (ICPT) Expected to Announce Earnings of -$3.38 Per Share

Equities research analysts expect that Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) will post earnings of ($3.38) per share for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Intercept Pharmaceuticals’ earnings. The highest EPS estimate is ($2.11) and the lowest is ($4.29). Intercept Pharmaceuticals posted earnings per share of ($4.84) in the same quarter last year, which suggests a positive year-over-year growth rate of 30.2%. The business is expected to announce its next earnings report on Thursday, February 22nd.

According to Zacks, analysts expect that Intercept Pharmaceuticals will report full-year earnings of ($13.50) per share for the current year, with EPS estimates ranging from ($14.27) to ($12.07). For the next year, analysts anticipate that the business will post earnings of ($11.92) per share, with EPS estimates ranging from ($15.66) to ($8.15). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Intercept Pharmaceuticals.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($3.48) by $0.59. The firm had revenue of $41.33 million for the quarter, compared to analyst estimates of $36.95 million. Intercept Pharmaceuticals had a negative return on equity of 152.78% and a negative net margin of 344.74%. The business’s quarterly revenue was up 697.9% compared to the same quarter last year. During the same period last year, the company earned ($3.59) EPS.

A number of equities research analysts have recently weighed in on the company. Laidlaw upgraded Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $90.00 price objective on the stock in a research report on Wednesday, November 1st. Wedbush reiterated an “outperform” rating and issued a $253.00 price objective on shares of Intercept Pharmaceuticals in a research report on Friday, August 25th. Royal Bank Of Canada lifted their price objective on Intercept Pharmaceuticals from $200.00 to $244.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 26th. Cowen and Company reiterated a “buy” rating and issued a $112.00 price objective on shares of Intercept Pharmaceuticals in a research report on Wednesday, November 1st. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Intercept Pharmaceuticals in a research report on Tuesday, September 26th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $153.76.

In other Intercept Pharmaceuticals news, CEO Mark Pruzanski sold 1,532 shares of Intercept Pharmaceuticals stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $58.87, for a total value of $90,188.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CMO David Shapiro sold 1,250 shares of Intercept Pharmaceuticals stock in a transaction on Friday, September 1st. The stock was sold at an average price of $117.43, for a total value of $146,787.50. Following the completion of the sale, the chief marketing officer now directly owns 45,812 shares of the company’s stock, valued at approximately $5,379,703.16. The disclosure for this sale can be found here. Insiders have sold 4,069 shares of company stock valued at $325,974 in the last quarter. 4.50% of the stock is owned by company insiders.

Several institutional investors have recently bought and sold shares of the business. PNC Financial Services Group Inc. increased its holdings in shares of Intercept Pharmaceuticals by 0.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,020 shares of the biopharmaceutical company’s stock worth $229,000 after purchasing an additional 14 shares in the last quarter. Public Employees Retirement Association of Colorado increased its holdings in shares of Intercept Pharmaceuticals by 1.1% in the 2nd quarter. Public Employees Retirement Association of Colorado now owns 4,111 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 43 shares in the last quarter. Janney Montgomery Scott LLC grew its holdings in shares of Intercept Pharmaceuticals by 1.8% in the second quarter. Janney Montgomery Scott LLC now owns 3,435 shares of the biopharmaceutical company’s stock worth $416,000 after acquiring an additional 62 shares during the period. WFG Advisors LP grew its holdings in shares of Intercept Pharmaceuticals by 16.4% in the second quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 125 shares during the period. Finally, Oppenheimer & Co. Inc. grew its holdings in shares of Intercept Pharmaceuticals by 9.0% in the first quarter. Oppenheimer & Co. Inc. now owns 2,152 shares of the biopharmaceutical company’s stock worth $244,000 after acquiring an additional 178 shares during the period. 82.69% of the stock is owned by institutional investors and hedge funds.

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) opened at $65.09 on Friday. The company has a debt-to-equity ratio of 2.05, a quick ratio of 6.61 and a current ratio of 6.61.

ILLEGAL ACTIVITY NOTICE: “Intercept Pharmaceuticals, Inc. (ICPT) Expected to Announce Earnings of -$3.38 Per Share” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.com-unik.info/2017/11/06/intercept-pharmaceuticals-inc-icpt-expected-to-announce-earnings-of-3-38-per-share.html.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Get a free copy of the Zacks research report on Intercept Pharmaceuticals (ICPT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intercept Pharmaceuticals (NASDAQ:ICPT)

What are top analysts saying about Intercept Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intercept Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit